Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
26 hedge funds and large institutions have $1.25M invested in Celgene Corporation Contingent Value Rights in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
4% less funds holding
Funds holding: 27 → 26 (-1)
13% less capital invested
Capital invested by funds: $1.43M → $1.25M (-$181K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
+$60.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$23.2K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$21.4K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
+$8.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$132K |
| 2 |
FA
FCG Advisors
Chatham,
New Jersey
|
-$102K |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$35K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 5 |
Morgan Stanley
New York
|
-$6.12K |
CELGZ Hedge Fund Activity: Q4 2016 in Review
26 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q4 2016, worth a combined $1.25M — down 13% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CELGZ and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Birchview Capital, adding an estimated $60.3K. The largest seller was Millennium Management, exiting entirely with an estimated $132K sold.
- 26 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q4 2016, down from 27 in Q3 2016.
- Funds reported $1.25M of Celgene Corporation Contingent Value Rights stock for Q4 2016, down 13% quarter-over-quarter.
- 3 funds opened new Celgene Corporation Contingent Value Rights positions in Q4 2016 and 4 closed out, a net change of -1 holder.
- The largest Celgene Corporation Contingent Value Rights buyer in Q4 2016 was Birchview Capital, an estimated $60.3K added.
- The largest Celgene Corporation Contingent Value Rights seller in Q4 2016 was Millennium Management, an estimated $132K sold.
Based on aggregated 13F filings for Q4 2016.